Detailed Abstract
[Poster Presentation 4 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP PP 4-S1] 3 Years Outcomes of Radical Surgery after Pre-operative Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Perihilar Cholangiocarcinoma
Eui Hyuk CHONG 1, Seok Jeong YANG 1, Kwang Hyun KIM 1, Incheon KANG 1, Sung Hwan LEE 1
1 Hepatobiliary And Pancreas, Department of Surgery, Bundang CHA, REPUBLIC OF KOREA
Background : We initiated this study to analyze the outcomes of radical surgery after preoperative nab-paclitaxel plus gemcitabine-cisplatin (Gem/Cis/nab-P) triplet chemotherapy in patients with perihilar cholangiocarcinoma.
Methods : We conducted a retrospective analysis of thirty-five patients who received preoperative chemotherapy with Gem/Cis/nab-P who subsequently underwent radical surgery for perihilar cholangiocarcinoma after discussion with multidisciplinary team (MDT) at a single institution.
Results : Thirty-five patients were included in this study. 20 were male and 15 were female patients. Mean age was 64 years (range, 39~73) with mean 6 (range, 4~10) cycles of preoperative chemotherapy. Every patient underwent major operation with mean operation time of 435 minutes (range, 305~1100). Among the cases reviewed, there were 29 major hepatectomies with common bile duct resection, five cases of hepatopancreatoduodenectomy, and one case of common bile duct resection. There were three major postoperative complications (14.2%) including two cases of postoperative mortality (5.71%). Notably, there were two complete remission cases (5.71%) in the final pathology. R0 resection was achieved in 31 patients (88.57%). The final pathological evaluation revealed a T stage of less than T2 in 32 patients (91.4%), and 24 patients (68.5%) showed no lymph node metastasis. After median postoperative follow-up duration of 20 months (1~38), recurrence occurred in 12 patients (34.2%) and mortality occurred in 5 (14.2%) patients. The 1, 2, 3 year recurrence-free and overall survival rates were 82.0%, 60.4% and 91.5%, 72.2%, respectively.
Conclusions : Over a 3-year postoperative monitoring period, preoperative Gem/Cis/nab-P chemotherapy with radical surgery shows favorable oncologic results with acceptable postoperative outcomes for patients with perihilar cholangiocarcinoma.
Methods : We conducted a retrospective analysis of thirty-five patients who received preoperative chemotherapy with Gem/Cis/nab-P who subsequently underwent radical surgery for perihilar cholangiocarcinoma after discussion with multidisciplinary team (MDT) at a single institution.
Results : Thirty-five patients were included in this study. 20 were male and 15 were female patients. Mean age was 64 years (range, 39~73) with mean 6 (range, 4~10) cycles of preoperative chemotherapy. Every patient underwent major operation with mean operation time of 435 minutes (range, 305~1100). Among the cases reviewed, there were 29 major hepatectomies with common bile duct resection, five cases of hepatopancreatoduodenectomy, and one case of common bile duct resection. There were three major postoperative complications (14.2%) including two cases of postoperative mortality (5.71%). Notably, there were two complete remission cases (5.71%) in the final pathology. R0 resection was achieved in 31 patients (88.57%). The final pathological evaluation revealed a T stage of less than T2 in 32 patients (91.4%), and 24 patients (68.5%) showed no lymph node metastasis. After median postoperative follow-up duration of 20 months (1~38), recurrence occurred in 12 patients (34.2%) and mortality occurred in 5 (14.2%) patients. The 1, 2, 3 year recurrence-free and overall survival rates were 82.0%, 60.4% and 91.5%, 72.2%, respectively.
Conclusions : Over a 3-year postoperative monitoring period, preoperative Gem/Cis/nab-P chemotherapy with radical surgery shows favorable oncologic results with acceptable postoperative outcomes for patients with perihilar cholangiocarcinoma.
SESSION
Poster Presentation 4
Zone E 3/21/2024 2:50 PM - 3:30 PM